Mesenchymal Stem Cell-Derived Extracellular Vesicles as Idiopathic Pulmonary Fibrosis Microenvironment Targeted Delivery

Lu Sang; Xiaoqin Guo; Haojun Fan; Jie Shi; Shike Hou; Qi Lv

doi:10.3390/cells11152322

Mesenchymal Stem Cell-Derived Extracellular Vesicles as Idiopathic Pulmonary Fibrosis Microenvironment Targeted Delivery

Cells. 2022 Jul 28;11(15):2322. doi: 10.3390/cells11152322.

Authors

Lu Sang^{1

2}, Xiaoqin Guo^{1

2}, Haojun Fan^{1

2}, Jie Shi^{1

2}, Shike Hou^{1

2}, Qi Lv^{1

2}

Affiliations

¹ Institute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300000, China.
² Tianjin Key Laboratory of Disaster Medicine Technology, Tianjin 300000, China.

Abstract

Idiopathic pulmonary fibrosis (IPF) affects an increasing number of people globally, yet treatment options remain limited. At present, conventional treatments depending on drug therapy do not show an ideal effect in reversing the lung damage or extending the lives of IPF patients. In recent years, more and more attention has focused on extracellular vesicles (EVs) which show extraordinary therapeutic effects in inflammation, fibrosis disease, and tissue damage repair in many kinds of disease therapy. More importantly, EVs can be modified or used as a drug or cytokine delivery tool, targeting injury sites to enhance treatment efficiency. In light of this, the treatment strategy of mesenchymal stem cell-extracellular vesicles (MSC-EVs) targeting the pulmonary microenvironment for IPF provides a new idea for the treatment of IPF. In this review, we summarized the inflammation, immune dysregulation, and extracellular matrix microenvironment (ECM) disorders in the IPF microenvironment in order to reveal the treatment strategy of MSC-EVs targeting the pulmonary microenvironment for IPF.

Keywords: bioengineering; extracellular vesicles; idiopathic pulmonary fibrosis; mesenchymal stem cells; microenvironment; targeted delivery.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Extracellular Vesicles*
Humans
Idiopathic Pulmonary Fibrosis* / therapy
Inflammation
Lung
Mesenchymal Stem Cells*

Grants and funding

This study was supported by funding from the National Natural Science Foundation of China, No. 81971878; the Opening Project of Military Logistics, No. BLB19J006; and the Tianjin Natural Science Foundation, No. 20JCQNJC01260; National Key Research and Development Program of China, No. 2021YFC3002202.